In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

This important study reveals a role for IκBα in the regulation of embryonic stem cell pluripotency. The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

XPO7 haploinsufficiency increases the risk of schizophrenia. In the mouse nervous system, it disrupts nuclear export or ...

A single amino acid change in a neuronal ion channel called KCNQ2 blocks ion flow, prevents protein localization on axons, and results in severe epilepsy and slowed neurological development.

The work has been reported in Nature Communications. SPLICER is a modification of the well known gene-editing technique known as CRISPR, in which a guide RNA takes a DNA-cutting enzyme called Cas9 to ...